Bio-Techne AI Adoption Tracker
Last updated: August 9, 2026
Overview
Bio-Techne Corporation has emerged as a leader in AI-enabled protein innovation and life sciences tools, with AI initiatives spanning product development, spatial biology, and biomarker discovery[1][2]. The company has commercialized several AI-enhanced designer proteins in 2025, leveraging generative AI trained on nearly five decades of proteomic data[2]. Key partnerships include licensing AI-designed NovoBody™ Duo molecules from Monod Bio and collaborating with Nucleai on AI-powered spatial biology workflows[3][4]. Bio-Techne's Science and Technology Committee has formally taken responsibility for AI application and ethical use across the business, reflecting board-level governance of AI strategy[5].
- [1] 2024 Bio-Techne Corporate Sustainability Report
- [2] ANNUAL REPORT 2025 - Bio-Techne
- [3] Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio
- [4] AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai
- [5] Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio
AI Maturity Index
Radar Comparison
Peer Comparison: Bio-Techne vs healthcare
Based on 66 companies in sector
| Dimension | Bio-Techne | Sector Avg | Diff |
|---|---|---|---|
| Adoption | 3.0 | 3.7 | -0.7 |
| Proficiency | 3.0 | 3.5 | -0.5 |
| Impact | 3.0 | 3.6 | -0.6 |
| Overall | 3.0 | 3.6 | -0.6 |
AI Hiring Signals
Bio-Techne Job Postings Analysis
Tech vs Non-Tech AI Requirements
Top Departments by AI Mention Rate
Analysis
Bio-Techne shows selective AI hiring with 6.5% of jobs mentioning AI skills. Notable pattern of AI requirements spreading beyond tech into Product (25%) and Legal (20%) roles, suggesting strategic AI governance and product development focus.
View Sample Job Postings (8 sources)
Key Metrics
AI Initiatives
3D Multiomics Automation with Wyss Center
December 2025
Strategic collaboration to develop automated workflow for simultaneous RNA and protein detection in 3D specimens
Partnership aims to overcome limitations of traditional approaches through AI-driven predictive modeling and reduce reliance on animal testing
Monod Bio AI Protein Partnership
November 2025
Licensing agreement for AI-designed NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins
Exclusive commercial rights to subset of Monod's NovoBody™ Duo molecules from Nobel Prize-winning David Baker lab, offering multi-specific binding capabilities
AI-Powered Spatial Biology with Nucleai
November 2025
Collaboration using Bio-Techne's COMET™ platform with Nucleai's AI-driven multimodal biomarker analysis
Clinical trial data from SECOMBIT study showcased AI-powered spatial biology workflow for predictive biomarker discovery in melanoma patients
AI-Enhanced Designer Protein Portfolio
January 2025
Launch of new designer proteins engineered using advanced AI-based design platforms and protein evolutionary workflows
Portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable, and Wnt/RSPO Agonist proteins with tailored functionalities like hyperactivity, enhanced receptor affinities, and heat stability
AI Governance and Ethics Framework
2025
Formal board-level oversight of AI application and ethical use in business operations
Science and Technology Committee took responsibility for AI application and ethical use, while conducting Double Materiality assessment
Frequently Asked Questions
Bio-Techne has developed AI-enhanced designer proteins including IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable, and Wnt/RSPO Agonist proteins with enhanced stability, hyperactivity, and improved receptor affinities.
Bio-Techne collaborates with Nucleai to combine its COMET™ platform with AI-driven multimodal analysis for predictive biomarker discovery, as demonstrated in melanoma clinical trial data.
The company's Science and Technology Committee has formal responsibility for AI application and ethical use, and they have conducted Double Materiality assessments to guide AI strategy.
The company's AI initiatives span protein engineering, spatial biology analysis, and biomarker discovery to accelerate therapeutic development and precision medicine applications.
In Application
| Application | Vendor | Use Case |
|---|---|---|
| Generative AI for Protein Design | Internal/Multiple | Design and engineering of next-generation cytokines and growth factors with enhanced properties |
| COMET™ Spatial Biology Platform | Bio-Techne (Lunaphore) | Automated high-throughput spatial biology analysis with AI integration |
| Nucleai Multimodal Spatial Operating System | Nucleai | Integration of high-plex imaging, histopathology, and clinical outcome data for biomarker discovery |
Sources
2024 Bio-Techne Corporate Sustainability Report
ANNUAL REPORT 2025 - Bio-Techne
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio
AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai
Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio
Related Companies
About AI Tracker
AI Tracker is a research project by Larridin, the AI execution intelligence platform.
Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.
Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.